K A Al-Barazanji1, J R Arch, R E Buckingham, M Tadayyon. 1. SmithKline Beecham Pharmaceuticals, Department of Vascular Biology, New Frontiers Science Park, Harlow, Essex, United Kingdom. kamal_A_Al-Barazanji@sbphrd.com
Abstract
OBJECTIVE: To investigate whether chronic administration of the long-acting glucagon-like peptide-1 receptor agonist exendin-4 can elicit sustained reductions in food intake and body weight and whether its actions require an intact leptin system. RESEARCH METHODS AND PROCEDURES: Male lean and obese Zucker (fa/fa) rats were infused intracerebroventricularly with exendin-4 using osmotic minipumps for 8 days. RESULTS: Exendin-4 reduced body weight in both lean and obese Zucker rats, maximum suppression being reached on Day 5 in obese (8%) and Day 7 in lean (16%) rats. However, epididymal white adipose tissue weight was not reduced, and only in lean rats was there a reduction in plasma leptin concentration. Food intake was maximally suppressed (by 81%) on Day 3 in obese rats but was reduced by only 18% on Day 8. Similarly, in lean rats food intake was maximally reduced (by 93%) on Day 4 of treatment and by 45% on Day 8. Brown adipose tissue temperature was reduced from Days 2 to 4. Plasma corticosterone was elevated by 76% in lean but by only 28% in obese rats. DISCUSSION: Chronic exendin-4 treatment reduced body weight in both obese and lean Zucker rats by reducing food intake: metabolic rate was apparently suppressed. These effects did not require an intact leptin system. Neither does the absence of an intact leptin system sensitize animals to exendin-4. Partial tolerance to the anorectic effect of exendin-4 in lean rats may have been due to elevated plasma corticosterone and depressed plasma leptin levels, but other counter-regulatory mechanisms seem to play a role in obese Zucker rats.
OBJECTIVE: To investigate whether chronic administration of the long-acting glucagon-like peptide-1 receptor agonist exendin-4 can elicit sustained reductions in food intake and body weight and whether its actions require an intact leptin system. RESEARCH METHODS AND PROCEDURES: Male lean and obese Zucker (fa/fa) rats were infused intracerebroventricularly with exendin-4 using osmotic minipumps for 8 days. RESULTS: Exendin-4 reduced body weight in both lean and obese Zucker rats, maximum suppression being reached on Day 5 in obese (8%) and Day 7 in lean (16%) rats. However, epididymal white adipose tissue weight was not reduced, and only in lean rats was there a reduction in plasma leptin concentration. Food intake was maximally suppressed (by 81%) on Day 3 in obeserats but was reduced by only 18% on Day 8. Similarly, in lean rats food intake was maximally reduced (by 93%) on Day 4 of treatment and by 45% on Day 8. Brown adipose tissue temperature was reduced from Days 2 to 4. Plasma corticosterone was elevated by 76% in lean but by only 28% in obeserats. DISCUSSION: Chronic exendin-4 treatment reduced body weight in both obese and lean Zucker rats by reducing food intake: metabolic rate was apparently suppressed. These effects did not require an intact leptin system. Neither does the absence of an intact leptin system sensitize animals to exendin-4. Partial tolerance to the anorectic effect of exendin-4 in lean rats may have been due to elevated plasma corticosterone and depressed plasma leptin levels, but other counter-regulatory mechanisms seem to play a role in obese Zucker rats.
Authors: Olivia M Farr; Michael A Tsoukas; Georgios Triantafyllou; Fadime Dincer; Andreas Filippaios; Byung-Joon Ko; Christos S Mantzoros Journal: Metabolism Date: 2016-03-18 Impact factor: 8.694
Authors: Roger D Reidelberger; Alvin C Haver; Prasanth K Chelikani; James L Buescher Journal: Am J Physiol Regul Integr Comp Physiol Date: 2008-06-11 Impact factor: 3.619
Authors: Sander Kooijman; Yanan Wang; Edwin T Parlevliet; Mariëtte R Boon; David Edelschaap; Gido Snaterse; Hanno Pijl; Johannes A Romijn; Patrick C N Rensen Journal: Diabetologia Date: 2015-08-09 Impact factor: 10.122